3Zia A,Schidberg FW,Funke I.MHC class Ⅰ negative phenotype of disseminated tumor cells in bone narrow is associated with poor survival in ROMO breast cancer patients[J].Int Cancer,2001,93(4):566.
4Jamil KA,Bharti O,Kanti DB.Immune responses in cancer[J].J Pharmacol Therapeut,2003,99:113-132.
5Ruiz-Cabello F,Garrido F.HLA and cancer:From research to clinical impact[J].Immunol Today,1998,19:539-542.
7Hicklin DJ,Marincola FM,Ferrone S,et al.HLA class Ⅰ antigen downregulation in human cancer:T-cell immunotherapy revives an old story[J].Mol Med Today,1999,5:178-186.
5[1]Mota FF, Rayment NB, Kanan JH, et al. Differential regulation of HLA-DR expression by keratinocytes and langerhanss cells in normal and premalignant cervical epithelium[J]. Tissue Antigens, 1998, 52 (3): 286-293.
6[2]Cabrera T, Ruiz-Caello F, Garrido F. Biological implications of HLA-DR expression in tumours[J]. Scand J Immunol, 1995, 41: 398-406.
7[3]Menge AC, Mestecky J. Surface expression of secretory component and HLA class Ⅱ DR antigen on glandular epithelial cells from human endometrium and two endometrial adenocarcinoma cell lines [J]. J Clin Immunol,1993, 13(4): 259-264.
8[6]Reinisch W, Holub M, Katz A, et al. Prospective pilot study of recombinant granulocyte-macrophage colonystimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma [J]. J Immunother,2002, 25(6): 489-499.
9[7]Wetzler M, McElwain BK, Stewart CC, et al. HLA-DR antigen-negative acute myeloid leukemia [J]. Leukemia,2003, 17(4): 707-715.
10[9]Lazaris AC, Theodoropoulos GE, Aroni K, et al. Immunohistochemical expression of C-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma[J]. Virchows Arch, 1995, 426 (5): 461-467.
1MITA AC,MITA MM,NAWROKI ST,et al. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics[J].Clin Cancer Res,2008,14(16):5000-5005.
2KITAMURA H,TORIGOE T,HONMA I,et al. Expression and antigenicity of survivin,an inhibitor of apoptosis family member,in bladder cancer: implications for specific immunotherapy[J].Urology,2006,67(5):955-959.
3KITAMURA H,HONMA I,TORIGOE T,et al. Down-Regulation of HLA Class I Antigen is an Independent Prognostic Factor for Clear Cell Renal Cell Carcinoma[J].J Urol,2007,177(4):1269-1272.
4AMBROSINI G,ADIDA C,ALTIERI DC,et al. A novel antiapoptosis gene, Survivin,expressed in cancer and lymphoma[J].Nat Med,1997,3(8):917-921.
5WANG GC,HSIEH PS,HSU HH,et al. Expression of cortactin and survivin in renal cell carcinoma associated with tumor aggressiveness[J]. World J Urol,2009,27(4):557-563.
6LU J,TAN M,HUANG WC,et al. Mitotic deregulation by Survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance[J]. Clin Cancer Res, 2009,15(4):1326-1334.
7SMITH SD,WHEELER MA,PLESCIA J,et al. Urine detection of surviving and diagnosis of bladder cancer[J].JAMA,2001,285(3):324-328.
8STICKEL JS,STICHEL N,Hennenlotter J,et al. Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation[J]. BMC Urology, 2011,11:1.
